A Zika Vaccine is Being Tested on Humans, But Public Release Still Months Away.

A researcher holds a container with female Aedes aegypti mosquitoes at the Biomedical Sciences Institute in the Sao Paulo's University, in Sao Paulo, Brazil, Monday, Jan. 18, 2016. The Aedes aegypti is a vector for transmitting the Zika virus. The Brazilian government announced it will direct funds to a biomedical research center to help develop a vaccine against the Zika virus linked to brain damage in babies. (AP Photo/Andre Penner)

The CDC cleared the way for two drug  companies to begin testing a Zika vaccine on humans. Inovio Pharmaceuticals  and South Korean based GeneOne Life Science dosed their first human subject last week  as part phase 1 safety trials.

During this phase, they’ll dose 40 healthy adult volunteers and to test the vaccine’s safety and the body’s immune system response.

If phase one is a success, they’ll begin phase two, which includes testing several more volunteers and examining patients’ antibodies that signal whether someone can fend off an infection. Finally, they’ll move into Phase three, the final step before getting approval to mass produce. This is when they’ll go into affected areas and give people either a vaccine or a placebo to allow researchers to figure out how effective the vaccine is against preventing the virus.

Phase one alone will take roughly 4 months, so researchers predict the vaccine won’t be approved for public use for at least a year.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s